Literature DB >> 8850544

Quantitation of phosphorothioate oligonucleotides in human plasma.

J M Leeds1, M J Graham, L Truong, L L Cummins.   

Abstract

Methods are presented for the extraction of phosphorothioate oligonucleotides from human plasma to permit quantitation by capillary gel electrophoresis. Extraction of the phosphorothioate oligonucleotides from plasma was accomplished using two solid-phase extraction columns, a strong anion-exchange column to remove plasma proteins and lipids, followed by a reverse-phase column to remove salts. A second desalting step, achieved by dialysis utilizing a membrane with a molecular weight cutoff of 2500 Da floating on distilled water, was required to remove residual ionic material from the extracted sample. This method should be generally applicable to the analysis and quantitation of phosphorothioate oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8850544     DOI: 10.1006/abio.1996.0088

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  18 in total

1.  New modalities in oncology: antisense oligonucleotides.

Authors:  C Casey Cunningham
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-04

2.  Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry.

Authors:  Xiaohui Wei; Guowei Dai; Zhongfa Liu; Hao Cheng; Zhiliang Xie; Guido Marcucci; Kenneth K Chan
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

3.  Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes.

Authors:  P L Nicklin; D Bayley; J Giddings; S J Craig; L L Cummins; J G Hastewell; J A Phillips
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

4.  Antisense oligonucleotide therapy for neurodegenerative disease.

Authors:  Richard A Smith; Timothy M Miller; Koji Yamanaka; Brett P Monia; Thomas P Condon; Gene Hung; Christian S Lobsiger; Chris M Ward; Melissa McAlonis-Downes; Hongbing Wei; Ed V Wancewicz; C Frank Bennett; Don W Cleveland
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

Review 5.  Capillary electrophoresis in pharmaceutical analysis.

Authors:  L A Holland; N P Chetwyn; M D Perkins; S M Lunte
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

6.  A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.

Authors:  Ranjana Advani; Bert L Lum; George A Fisher; Joanne Halsey; Richard S Geary; Jon T Holmlund; T Jesse Kwoh; F Andrew Dorr; Branimir I Sikic
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

7.  Distribution of a 20-mer phosphorothioate oligonucleotide, CGP69846A (ISIS 5132), into airway leukocytes and epithelial cells following intratracheal delivery to brown-norway rats.

Authors:  H Danahay; J Giddings; R A Christian; H E Moser; J A Phillips
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

8.  Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes.

Authors:  R Z Yu; R S Geary; J M Leeds; T Watanabe; J R Fitchett; J E Matson; R Mehta; G R Hardee; M V Templin; K Huang; M S Newman; Y Quinn; P Uster; G Zhu; P K Working; M Horner; J Nelson; A A Levin
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

9.  Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.

Authors:  B R Yacyshyn; W Y Chey; J Goff; B Salzberg; R Baerg; A L Buchman; J Tami; R Yu; E Gibiansky; W R Shanahan
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

10.  Downregulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake.

Authors:  Jianjun Zhang; Mohammad Zafrullah; Xia Yang; Xianglei Yin; Zhigang Zhang; Zvi Fuks; Richard Kolesnick
Journal:  Cancer Biol Ther       Date:  2008-09-15       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.